Skip to Content

Case Study

Pharmacogenomic Study Rescued With On-Time Database Lock and 100% Subject Retention

A top 50 pharmaceutical company needed to establish bioequivalence between two formulations of a drug used to treat multiple sclerosis. The study was ongoing but burdened with enrollment and retention problems due to various complex requirements, including finding subjects that fit a specific genotype. The retention problem was problematic as the subjects that did not complete the study represented a significant loss of study data.


Back to Resources

Ready to partner with Spaulding Clinical for your Phase I study?

Let’s Talk